Hemodialysis (HD) patients have altered free triiodothyronine (fT3) levels. A low fT3 level is a strong and inverse mortality predictor in HD patients. However, little is known about the relationship between fT3 and left ventricular function in HD patients.
Methods
A total of 128 maintenance HD patients were enrolled in this study. A thyroid function test with blood sampling and echocardiography was conducted. Low-T3 syndrome was defined as fT3 level <3.62 pmol/L and normal thyroid stimulating hormone (TSH). Overall mortality and rate of cardiovascular (CV) events were assessed during 48 months of follow-up.
Results
Low-T3 syndrome was detected in 57 (44.5%) of the 128 patients. Patients with low-T3 syndrome had a shorter duration of HD (49.1 vs. 73.3, p = 0.01), and lower serum albumin (35.1 vs. 40.4 g/L, p<0.001), left ventricular ejection fraction (LVEF; 54.7% vs. 63.9%, p<0.001), and fractional shortening at endocardial levels (endoFS; 29.3% vs. 34.8%, p = 0.001) compared to those with normal fT3 levels. In multivariate linear regression, LVEF, albumin, and duration of HD were independently correlated with fT3 levels. In addition, fT3 was also correlated with LVEF. During the study period, 13 (10.1%) patients died, CV events occurred in 15 (11.7%) patients. In Cox regression analysis, low fT3 level and elevated high-sensitivity C-reactive protein (hs-CRP) were associated with mortality and CV events.
Conclusions
In HD patients, fT3 level is positively correlated with LVEF. Low fT3 level and elevated hs-CRP predicted all-cause mortality and CV events.
RodriguesM.C., SantosG.M., da SilvaC.A.. Thyroid hormone transport is disturbed in erythrocytes from patients with chronic renal failure on hemodialysis. Ren Fail.2004; 26(4): 461–466.
6.
MeuweseC.L., DekkerF.W., LindholmB.. Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol.2012; 7(1): 131–138.
7.
TatarE., KircelliF., AsciG.. Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clin J Am Soc Nephrol.2011; 6(9): 2240–2246.
8.
ZoccaliC., BenedettoF., MallamaciF.. Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. J Hypertens.2006; 24(10): 2039–2046.
9.
OzenK.P., AsciG., GungorO.. Nutritional state alters the association between free triiodothyronine levels and mortality in hemodialysis patients. Am J Nephrol.2011; 33(4): 305–312.
10.
YavuzD., SezerS., YavuzR.. Free triiodothyronine in hemodialysis patients: link with malnutrition and inflammation. Iran J Kidney Dis.2014; 8(3): 212–217.
11.
Franczyk-SkoraB., GlubaA., BanachM.. Prevention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrol.2012; 13: 162.
12.
DrechslerC., SchneiderA., Gutjahr-LengsfeldL.. Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patients. Am J Kidney Dis.2014; 63(6): 988–996.
13.
GoodkinD.A., Bragg-GreshamJ.L., KoenigK.G.. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol.2003; 14(12): 3270–3277.
14.
LucasC., JohnsonW., HamiltonM.A.. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J.2000; 140(6): 840–847.
15.
RosnerM.H., RoncoC.Techniques for the assessment of volume status in patients with end stage renal disease. Semin Dial.2014; 27(6): 538–541.
16.
SessoH.D., StampferM.J., RosnerB.. Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men. Hypertension.2000; 36(5): 801–807.
17.
CharlsonM.E., PompeiP., AlesK.L., MacKenzieC.R.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis.1987; 40(5): 373–383.
18.
FriedL., BernardiniJ., PirainoB.Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis.2001; 37(2): 337–342.
19.
Di IorioB., CilloN., CirilloM., De SantoN.G.Charlson Comorbidity Index is a predictor of outcomes in incident hemodialysis patients and correlates with phase angle and hospitalization. Int J Artif Organs.2004; 27(4): 330–336.
20.
StefánssonB.V., BrunelliS.M., CabreraC.. Intradialytic hypotension and risk of cardiovascular disease. Clin J Am Soc Nephrol.2014; 9(12): 2124–2132.
21.
SandsJ.J., UsvyatL.A., SullivanT.. Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome. Hemodial Int.2014; 18(2): 415–422.
22.
YildizA., OflazH., PusurogluH.. Left ventricular hypertrophy and endothelial dysfunction in chronic hemodialysis patients. Am J Kidney Dis.2003; 41(3): 616–623.
23.
LiuY.W., SuC.T., SungJ.M.. Association of left ventricular longitudinal strain with mortality among stable hemodialysis patients with preserved left ventricular ejection fraction. Clin J Am Soc Nephrol.2013; 8(9): 1564–1574.
24.
DevereuxR.B., AlonsoD.R., LutasE.M.. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol.1986; 57(6): 450–458.
25.
EniaG., PanuccioV., CutrupiS.. Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant.2007; 22(2): 538–544.
26.
LangR.M., BierigM., DevereuxR.B..; Chamber Quantification Writing Group; American Society of Echocardiographys Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiographys Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr.2005; 18(12): 1440–1463.
27.
SongS.H., KwakI.S., LeeD.W., KangY.H., SeongE.Y., ParkJ.S.The prevalence of low triiodothyronine according to the stage of chronic kidney disease in subjects with a normal thyroid-stimulating hormone. Nephrol Dial Transplant.2009; 24(5): 1534–1538.
28.
XuJ.G., XieR.S., HeY.C.The changes of seum thyroid hormone in patients with chronic renal failure and its clinical significance. J Guangdong medical college.2015; 33(2): 169–171.
29.
LoJ.C., ChertowG.M., GoA.S., HsuC.Y.Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int.2005; 67(3): 1047–1052.
30.
Fernandez-ReyesM.J., SánchezR., HerasM.. [Can FT3 levels facilitate the detection of inflammation or catabolism and malnutrition in dialysis patients?]. Nefrologia.2009; 29(4): 304–310.
31.
BoelenA., KwakkelJ., WiersingaW.M., FliersE.Chronic local inflammation in mice results in decreased TRH and type 3 deiodinase mRNA expression in the hypothalamic paraventricular nucleus independently of diminished food intake. J Endocrinol.2006; 191(3): 707–714.
32.
CerilloA.G., StortiS., KallushiE.. The low triiodothyronine syndrome: a strong predictor of low cardiac output and death in patients undergoing coronary artery bypass grafting. Ann Thorac Surg.2014; 97(6): 2089–2095.
33.
ChenY.F., WeltmanN.Y., LiX., YoumansS., KrauseD., GerdesA.M.Improvement of left ventricular remodeling after myocardial infarction with eight weeks L-thyroxine treatment in rats. J Transl Med.2013; 11: 40–50.
34.
ZoccaliC., MallamaciF., TripepiG., CutrupiS., PizziniP.Low triiodothyronine and survival in end-stage renal disease. Kidney Int.2006; 70(3): 523–528.
35.
YangJ.W., HanS.T., SongS.H.. Serum T3 level can predict cardiovascular events and all-cause mortality rates in CKD patients with proteinuria. Ren Fail.2012; 34(3): 364–372.
36.
de MutsertR., GrootendorstD.C., AxelssonJ., BoeschotenE.W., KredietR.T., DekkerF.W.; NECOSAD Study Group. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant.2008; 23(9): 2957–2964.
